Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2026

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from $12.17 billion in 2025 to $12.36 billion in 2026 at a compound annual growth rate (CAGR) of 1.6%. The growth in the historic period can be attributed to approval of lucentis and eylea, rising prevalence of age-related macular degeneration, growing incidence of diabetic retinopathy, advancements in molecular biology for angiogenesis inhibition, expansion of hospital ophthalmology services.

The anti-vascular endothelial growth factor therapeutics market size is expected to see steady growth in the next few years. It will grow to $13.59 billion in 2030 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to launch of next-generation anti-vegf therapeutics, increased investment in precision oncology, growing biosimilar market penetration, rising healthcare expenditure in emerging markets, adoption of combination therapies in retinal diseases. Major trends in the forecast period include increasing adoption of anti-vegf therapies in ophthalmology, growth of targeted cancer therapies, development of biosimilar anti-vegf drugs, rising geriatric population driving amd treatments, expansion of outpatient and specialty clinics.

The growing prevalence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market in the coming years. The prevalence of ophthalmic diseases refers to the proportion or number of people within a population who have been diagnosed with or are affected by specific eye disorders or conditions. Anti-vascular endothelial growth factor (VEGF) therapeutics play a critical role in reducing the burden of ophthalmic diseases by effectively treating conditions such as wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. For example, in August 2023, the World Health Organization, a Switzerland-based international public health body, reported that approximately 2.2 billion people worldwide experience near or distance vision impairment, of whom 1 billion suffer from vision impairment that could have been prevented or has yet to be addressed. Among these individuals, around 88.4 million are affected by refractive errors, 94 million by cataracts, 8 million by age-related macular degeneration, and nearly 3.9 million by diabetic retinopathy. Consequently, the rising prevalence of ophthalmic diseases is contributing to the growth of the anti-vascular endothelial growth factor therapeutics market.

Leading companies operating in the anti-VEGF therapeutics market are increasingly engaging in strategic partnerships to speed up the development, commercialization, and uptake of VEGF inhibitor therapies. These collaborations enable companies to combine complementary expertise, gain access to advanced technologies, and broaden their market reach. For instance, in January 2025, Teva Pharmaceuticals International GmbH, a Switzerland-based subsidiary of Teva Pharmaceutical Industries focused on biosimilars and complex generics, entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG to commercialize FYB203, a biosimilar candidate to Eylea (aflibercept), across Europe excluding Italy and in Israel. Through this agreement, Teva utilizes its well-established commercial infrastructure and distribution capabilities to reinforce its position in the anti-VEGF therapeutics market. In this partnership, Formycon AG is responsible for the development of FYB203, while Klinge Biopharma GmbH holds exclusive global commercialization rights for the product.

In February 2025, BioNTech SE, a Germany-based biotechnology company specializing in immunotherapies and biologics, acquired Biotheus for $950 million. With this acquisition, BioNTech seeks to enhance its VEGF-focused therapeutic pipeline by obtaining full global rights to BNT327/PM8002, an investigational PD-L1 × VEGF-A bispecific antibody, along with access to Biotheus’ proprietary antibody development platform. Biotheus is a China-based biopharmaceutical company engaged in the development of anti-VEGF therapeutics.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the anti-vascular endothelial growth factor therapeutics market by increasing the cost of imported active pharmaceutical ingredients and biologics, affecting supply chains for drugs like Eylea, Lucentis, and Beovu. The ophthalmology and oncology segments, particularly in regions such as North America and Europe reliant on imports, face higher production costs and potential delays. While tariffs may increase local manufacturing incentives and encourage regional production of biosimilars, the short-term effect has been higher treatment costs and slowed adoption across clinics and hospitals.

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports that provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with a anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-vascular endothelial growth factor (VEGF) therapeutics are medications that block the formation of new blood vessels and are widely used in the treatment of ophthalmic disorders. These drugs work by inhibiting vascular endothelial growth factors and are also applied in the treatment of certain tumors and age-related macular degeneration.

The key products in the anti-vascular endothelial growth factor therapeutics category include Eylea, Lucentis, and Beovu. Eylea is a medication used to treat specific eye conditions such as macular degeneration and diabetic retinopathy. It functions as an anti-vascular endothelial growth factor therapeutic by preventing abnormal blood vessel growth in the eye, which is commonly linked to retinal disorders. Anti-vascular endothelial growth factor therapeutics are used to treat macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration and are utilized by hospitals, clinics, oncology centers, and other end users.

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.